Open AccessPhase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
Author(s) -
A. Bardia,
A. Gucalp,
N. DaCosta,
N. Gabrail,
M. Danso,
H. Ali,
K.L. Blackwell,
L.A. Carey,
J.R. Eisner,
E.S. Baskin-Bey,
T.A. Traina
Publication year - 2018
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/9rq4-3h72
Subject(s) - androgen receptor , estrogen receptor , triple negative breast cancer , breast cancer , estrogen , medicine , receptor , progesterone receptor , cancer research , chemistry , endocrinology , cancer , prostate cancer